PL2886108T5 - Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku - Google Patents

Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku

Info

Publication number
PL2886108T5
PL2886108T5 PL13199278.6T PL13199278T PL2886108T5 PL 2886108 T5 PL2886108 T5 PL 2886108T5 PL 13199278 T PL13199278 T PL 13199278T PL 2886108 T5 PL2886108 T5 PL 2886108T5
Authority
PL
Poland
Prior art keywords
optimised
esophagus
treatment
inflammatory changes
pharmaceutical formula
Prior art date
Application number
PL13199278.6T
Other languages
English (en)
Other versions
PL2886108T3 (pl
Inventor
Roland Greinwald
Ralph Müller
Markus PRÖLS
Rudolf Wilhelm
Original Assignee
Dr. Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49911300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2886108(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr. Falk Pharma Gmbh filed Critical Dr. Falk Pharma Gmbh
Publication of PL2886108T3 publication Critical patent/PL2886108T3/pl
Publication of PL2886108T5 publication Critical patent/PL2886108T5/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13199278.6T 2013-12-23 2013-12-23 Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku PL2886108T5 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13199278.6A EP2886108B2 (de) 2013-12-23 2013-12-23 Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus

Publications (2)

Publication Number Publication Date
PL2886108T3 PL2886108T3 (pl) 2019-08-30
PL2886108T5 true PL2886108T5 (pl) 2023-02-27

Family

ID=49911300

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13199278.6T PL2886108T5 (pl) 2013-12-23 2013-12-23 Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku
PL14814872T PL3086782T3 (pl) 2013-12-23 2014-12-18 Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14814872T PL3086782T3 (pl) 2013-12-23 2014-12-18 Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku

Country Status (23)

Country Link
US (4) US9867780B2 (pl)
EP (2) EP2886108B2 (pl)
JP (3) JP6522626B2 (pl)
CN (1) CN105848648B (pl)
AU (1) AU2014372739B2 (pl)
CA (1) CA2934009C (pl)
CY (2) CY1121168T1 (pl)
DK (2) DK2886108T4 (pl)
EA (1) EA029166B1 (pl)
ES (2) ES2716990T5 (pl)
FI (1) FI2886108T4 (pl)
HR (2) HRP20190677T4 (pl)
HU (2) HUE042009T2 (pl)
IL (1) IL246172B (pl)
LT (2) LT2886108T (pl)
PL (2) PL2886108T5 (pl)
PT (2) PT2886108T (pl)
RS (2) RS58543B2 (pl)
SI (2) SI2886108T2 (pl)
TR (1) TR201815823T4 (pl)
UA (1) UA117162C2 (pl)
WO (1) WO2015097053A1 (pl)
ZA (1) ZA201604225B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106421797A (zh) 2009-10-01 2017-02-22 艾戴尔医药公司 口服给予的皮质类固醇组合物
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
PL2886108T5 (pl) 2013-12-23 2023-02-27 Dr. Falk Pharma Gmbh Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
WO2020084530A1 (en) 2018-10-24 2020-04-30 Ferring B.V. Mucoadhesive pharmaceutical compositions of corticosteroids
EP4091615A1 (en) 2021-05-20 2022-11-23 Dr. Falk Pharma Gmbh Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis
CN116869927B (zh) * 2023-09-06 2023-11-10 中国医学科学院北京协和医院 一种用于治疗嗜酸性食管炎的食道温敏凝胶

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3937455A1 (de) * 1989-11-10 1991-05-16 Nordmark Arzneimittel Gmbh Antacidatabletten
DE59106133D1 (de) * 1990-10-19 1995-09-07 Spirig Ag Feste, schnell-lösliche Arzneimittelzubereitung enthaltend S-(Carboxymethyl)-L-Cystein und/oder N-Acetylcystein.
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2834893B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de perindopril
JP2005526095A (ja) 2002-03-20 2005-09-02 エラン ファーマ インターナショナル,リミティド 脆砕性の低い急速溶解投与剤型
JP4475233B2 (ja) 2003-01-21 2010-06-09 日本新薬株式会社 口腔内速崩性錠剤
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060013873A1 (en) 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20070071817A1 (en) 2005-09-26 2007-03-29 Phyzz, Inc. Effervescent oral care compositions and method of use
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070191323A1 (en) 2006-02-15 2007-08-16 Verus Pharmaceuticals, Inc. Stable corticosteroid mixtures
WO2009043844A2 (en) 2007-10-01 2009-04-09 Laboratorios Lesvi, S.L. Orodispersible tablets
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
PT2151235E (pt) 2008-07-21 2011-03-21 Falk Pharma Gmbh Formulação farmacêutica para o tratamento do trato digestivo superior
AU2009279521A1 (en) 2008-08-08 2010-02-11 Mcneil-Ppc, Inc. Use of sucralose as a granulating agent
CA2765033C (en) * 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
PL2886108T5 (pl) * 2013-12-23 2023-02-27 Dr. Falk Pharma Gmbh Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku

Also Published As

Publication number Publication date
JP2020196753A (ja) 2020-12-10
EA029166B1 (ru) 2018-02-28
EP3086782A1 (de) 2016-11-02
FI2886108T4 (fi) 2023-02-22
HUE042009T2 (hu) 2019-06-28
IL246172A0 (en) 2016-07-31
HK1209362A1 (en) 2016-04-01
ZA201604225B (en) 2017-08-30
RS58543B1 (sr) 2019-04-30
CY1121168T1 (el) 2020-05-29
ES2694331T3 (es) 2018-12-19
RS58543B2 (sr) 2023-02-28
PT3086782T (pt) 2018-11-19
AU2014372739B2 (en) 2019-06-13
CN105848648A (zh) 2016-08-10
HUE041911T2 (hu) 2019-06-28
SI3086782T1 (sl) 2018-11-30
HRP20190677T4 (hr) 2023-02-03
DK3086782T3 (en) 2018-11-26
LT3086782T (lt) 2018-11-26
DK2886108T3 (en) 2019-04-01
JP7009575B2 (ja) 2022-01-25
US20200337997A1 (en) 2020-10-29
ES2716990T5 (es) 2023-03-24
US10695291B2 (en) 2020-06-30
JP2019142931A (ja) 2019-08-29
TR201815823T4 (tr) 2018-11-21
US20180185277A1 (en) 2018-07-05
UA117162C2 (uk) 2018-06-25
IL246172B (en) 2019-01-31
US10369100B2 (en) 2019-08-06
JP2017500361A (ja) 2017-01-05
JP6757444B2 (ja) 2020-09-16
WO2015097053A1 (de) 2015-07-02
US11382860B2 (en) 2022-07-12
EP2886108A1 (de) 2015-06-24
CA2934009A1 (en) 2015-07-02
EP2886108B2 (de) 2022-11-02
PL2886108T3 (pl) 2019-08-30
LT2886108T (lt) 2019-03-25
CA2934009C (en) 2020-03-10
HRP20181799T1 (hr) 2018-12-28
SI2886108T1 (sl) 2019-05-31
US20190358155A1 (en) 2019-11-28
HRP20190677T1 (hr) 2019-05-31
ES2716990T3 (es) 2019-06-18
PT2886108T (pt) 2019-04-01
CY1121523T1 (el) 2020-05-29
EP2886108B1 (de) 2019-02-06
SI2886108T2 (sl) 2023-02-28
PL3086782T3 (pl) 2019-03-29
JP6522626B2 (ja) 2019-05-29
EA201600497A1 (ru) 2017-03-31
AU2014372739A1 (en) 2016-07-07
US9867780B2 (en) 2018-01-16
NZ721495A (en) 2020-12-18
DK2886108T4 (da) 2023-01-30
US20160324772A1 (en) 2016-11-10
EP3086782B1 (de) 2018-09-26
CN105848648B (zh) 2019-08-06
RS58112B1 (sr) 2019-02-28

Similar Documents

Publication Publication Date Title
IL243976A0 (en) kdm1a inhibitors for disease treatment
SI3269716T1 (sl) Nove spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj
PT3086782T (pt) Formulação farmacêutica otimizada para o tratamento de alterações inflamatórias do esófago
PL3062790T3 (pl) Połączenia farmaceutyczne do leczenia raka
IL242546A0 (en) New compounds for cancer treatment
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
ZA201507724B (en) The treatment of inflammatory disorders
EP3089984A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
GB2528413B (en) Inhibition of IL-2 production
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201306411D0 (en) Treatment of inflammatory conditions
IL241331B (en) Delay of degenerative diseases
GB201321628D0 (en) Treatment of disease
AP2015008905A0 (en) Novel compounds for the treatment of cancer
GB201314015D0 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
GB201315079D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201314016D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201303721D0 (en) Compositions for treatment of sleep disorders
AU2013900139A0 (en) Device for the treatment of snoring